Boston Scientific Announces $20 B 2025 Sales Target at AGM; Board Resolutions Pass, Special Meeting Requests Rejected

At its annual general meeting, Boston Scientific disclosed a sales target of $20 billion for 2025, underscoring the company’s growth strategy and product portfolio expansion. Board and stakeholder‑proposed governance measures were approved by vote, reinforcing the firm’s commitment to transparency and stakeholder engagement. A special meeting request submitted by certain shareholders was rejected by a majority vote, indicating that the current board decisions will remain in effect. This is not investment advice.

📊 BSX — Piyasa Yorumu

▲ up · 60%

Boston Scientific has set its 2025 sales target at $20 billion, and the board’s votes have successfully passed, reinforcing the company’s growth expectations. The rejection of special meeting proposals signals management’s confidence in the current strategy. Technical indicators show the price trading slightly above the 20‑day moving average, below the 50‑day moving average, and an RSI around 48, suggesting a modest short‑term upside potential. In the 1‑ to 3‑day window, the positive news could lift the price by 1‑2 %. However, market volatility and other macro factors may also influence the price, so careful monitoring is advised.

RSI 14

48.5

MACD

-0.01

24h Δ

-1.14%

Canlı Grafikler